Pfizer faces significant hurdles next year, starting with its late entry into the GLP-1 weight-loss drug market where competitors have already secured peak demand. The company’s two blockbuster oncology and cardiovascular therapies— Ibrance, which loses exclusivity in 2027, and Eliquis alongside Vyndaqel, both off-patent in 2028—accounted for nearly 30% of revenues in 2023. As generics begin eroding sales, Pfizer’s overall product revenues could decline by as much as 15% between 2026 and 2028. Furthermore, the firm’s dividend payout ratio is approaching 100%, driven by slower cash flows that threaten future distributions and could force a reduction in its 4.1% yield to maintain financial flexibility.

Analysts anticipate a slide in fourth-quarter earnings, projecting 57 cents per share compared with 63 cents in the year-ago period, while revenues are expected to drop from $17.76 billion to $16.83 billion. Ahead of the February 3 earnings release, the most accurate forecasting firms have adjusted their estimates downward by an average of 8% for EPS and 5% for top-line figures. These revisions reflect ongoing challenges in COVID-related vaccine sales, which declined by 40% year-over-year in Q3, and slower uptake in new therapy launches. Investors will closely watch guidance for 2026, where analysts currently forecast mid‐single-digit revenue growth, heavily reliant on pipeline readouts.

On January 20, Pfizer secured an exclusive license agreement with Novavax for the Matrix-M adjuvant, bolstering its vaccine development capabilities. Matrix-M has demonstrated a 60% enhancement in immune response when combined with recombinant protein antigens in clinical trials. This partnership expands Pfizer’s adjuvant portfolio and supports upcoming phase III studies in both influenza and respiratory syncytial virus candidates. Management expects this deal to contribute up to $500 million in incremental revenues by 2027, partly offsetting declines from expiring patents and reinforcing the long-term growth trajectory of Pfizer’s vaccine division.